US Patent

US12350262 — Methods of treatment for cystic fibrosis

Method of Use · Assigned to Vertex Pharmaceuticals Inc · Expires 2038-07-17 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using a pharmaceutical composition containing Compound I to treat cystic fibrosis.

USPTO Abstract

Compound I of the formulaand/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4221`	—
`U-4220`	—
`U-4222`	—

Patent Metadata

Patent number: US12350262
Jurisdiction: US
Classification: Method of Use
Expires: 2038-07-17
Drug substance claim: No
Drug product claim: No
Assignee: Vertex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.